Pharmafile Logo
Pharmafocus logo
Advanced Search

Tagrisso

Showing 15 posts of 24 posts found.

AstraZeneca’s Tagrisso approved by FDA for lung cancer treatment

February 19, 2024
Medical Communications AstraZeneca, Oncology, Tagrisso, lung cancer

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Tagrisso for the treatment of adult patients …

News

AstraZeneca announces positive results from phase 3 trial for Tagrisso plus chemotherapy

May 17, 2023
Research and Development AstraZeneca, Cancer, Oncology, Tagrisso, chemotherapy

AstraZeneca has announced positive results from the FLAURA2 phase 3 trial which showed that Tagrisso (osimertinib), in combination with chemotherapy, …

News
astrazeneca-sign

FDA grants priority review to AstraZeneca’s Tagrisso as an adjuvant for early-stage EGFR-mutated non-small cell lung cancer

October 20, 2020
Manufacturing and Production, Sales and Marketing AstraZeneca, FDA, Tagrisso

The FDA has revealed its decision to grant Priority Review to AstraZeneca’s Tagrisso (osimertinib) as an adjuvant treatment of patients …

News
astrazeneca_sign_sky

NICE U-turns to approve AstraZeneca’s Tagrisso in two new lung cancer indications

September 11, 2020
Medical Communications, Sales and Marketing AstraZeneca, NICE, Tagrisso

NICE has announced the recommendation of AstraZeneca’s Tagrisso (osimertinib) for routine use on the NHS in England and Wales in …

News

No NICE recommendation for AstraZeneca’s Tagrisso in EGFR+ lung cancer

January 22, 2020
Research and Development, Sales and Marketing AstraZeneca, NICE, Tagrisso, pharma

AstraZeneca’s Tagrisso (osimertinib) has been knocked back for routine use on the NHS in England and Wales by the drug …

News
astrazeneca_building_white

AZ’s Tagrisso extends median overall survival by over 3 years in metastatic, EGFR-mutated lung cancer

September 30, 2019
Research and Development, Sales and Marketing AstraZeneca, Cancer, ESMO 2019, Tagrisso, lung cancer, pharma

AstraZeneca took to the stage at the 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona to present new …

News
astrazeneca_plaque

AZ’s Tagrisso secures China approval in first-line advanced lung cancer

September 4, 2019
Research and Development, Sales and Marketing AstraZeneca, China, Tagrisso, lung cancer, pharma

AstraZeneca’s Tagrisso (osimertinib) has secured approval in China from the country’s National Medical Products Administration (NMPA) in the first-line treatment …

News
astrazeneca_plaque

AstraZeneca’s Tagrisso improves overall survival in lung cancer in Phase 3 trial

August 9, 2019
Medical Communications AstraZeneca, Cancer, Tagrisso, lung cancer, oncology, pharma

AstraZeneca has said its cancer drug Tagrisso significantly improved overall survival in a Phase 3 study of patients with lung …

News
astrazeneca_sign_sky

Japan approves AstraZeneca’s Tagrisso in EGFRm non-small cell lung cancer

August 21, 2018
Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, Japan, Tagrisso, lung cancer, pharma

AstraZeneca has revealed that its EGFR tyrosine kinase inhibitor Tagrisso (osimertinib) has been approved in Japan by the nation’s Ministry …

News
astrazeneca_logo_building

EU gives nod to expanded label for AZ’s Tagrisso

June 11, 2018
Sales and Marketing AstraZeneca, Tagrisso, biotech, drugs, pharma, pharmaceutical

AstraZeneca has scored another success with Tagrisso in Europe, by receiving an expanded marketing authorisation for Tagrisso in the first-line …

News
astrazeneca_building_white

AZ’s Tagrisso gets FDA nod in first-line EGFR-mutated lung cancer

April 19, 2018
Sales and Marketing AstraZeneca, Cancer, EGFR-TKIs, NSCLC, Tagrisso, lung cancer, pharma

AstraZeneca has announced that its epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) has received approval from …

News
shutterstock_79370437

Hanmi terminates lung cancer drug after being muscled out by AZ’s Tagrisso

April 13, 2018
Medical Communications, Research and Development AstraZeneca, Cancer, Otila, Tagrisso, hanmi, lung cancer, pharma

South Korea’s Hanmi Pharmaceutical has announced its intention to terminate development of its lung cancer drug Olita (olmutinib) as it …

News
astrazeneca_plaque

AstraZeneca’s Tagrisso beats standard of care in halting NSCLC

September 11, 2017
Research and Development, Sales and Marketing AstraZeneca, ESMO, NSCLC, Tagrisso, non-small cell cell cancer, pharma, pharmaceutical

AstraZeneca has revealed new data at the European Society of Medical Oncology (ESMO) on the efficacy of Tagrisso (osimertinib) in …

News
astrazeneca_building_white

AZ’s Tagrisso continues successes with EU approval

April 26, 2017
Research and Development, Sales and Marketing AstraZeneca, EU, European Commission, NSCLC, Tagrisso

More good news for AstraZeneca’s Tagrisso (osimertinib), as the company announces that the European Commission has granted the drug full …

News
astrazeneca_sign_sky

AstraZeneca ends month with two pieces of news

March 31, 2017
Medical Communications, Sales and Marketing AstraZeneca, Tagrisso, TerSera Therapeutics, Zoladex

AstraZeneca has ended the month with more positive news on Tagrisso, that had previously been approved in China under its …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024